<DOC>
	<DOC>NCT00836940</DOC>
	<brief_summary>The study is aimed at evaluating efficacy and safety of GRC 8200 in type 2 diabetes mellitus patients. The study involves six weeks of wash out period and two weeks run in period for patients currently on mono-therapy and a two week run in period only for drug naïve patients. This is a placebo controlled study. One of the five treatment arms is placebo. The duration of treatment is 12 weeks.</brief_summary>
	<brief_title>A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Male or female patients ≥30 years of age At screening, females of nonchildbearing potential or females of childbearing potential with adequate contraception Has an established clinical diagnosis of type 2 diabetes mellitus for at least 3 months prior to the screening period Is being treated for diabetes either with diet and exercise alone, or on monotherapy with any of the antidiabetic drugs Has an HbA1c value at screening between 6.5% and 10% Has type 1 diabetes Is a female who is lactating or is pregnant Has a history of acute metabolic diabetic complications Has clinically significant disease other than type 2 diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>GRC 8200</keyword>
</DOC>